The racemic version of a CYP450 metabolite of arachidonic acid that dose-dependently stimulates vasodilation of the rabbit kidney.

A non-enzymatic hydrolysis product of LTA4 with reduced activity compared to LTB4; also produced by oxidative decomposition of CysLTs such as LTC4 in the presence of myeloperoxidase and hypochlorous acid.

A major CYP450 metabolite of arachidonic acid that is released from the kidney in response to angiotensin II; a potent vasodilator of renal preglomerular vessels; blocks 20-HETE-induced vasoconstriction of renal arterioles at 1 µM.

A potent anti-fungal antibiotic that can directly block nuclear transport by inhibiting the action of CRM1.

Major β-oxidation product resulting from peroxisomal metabolism of 12(S)-HETE

15-OxoETE is produced by oxidation of the 15-hydroxyl of 15-HETE. Whether this is a major pathway of 15-HETE metabolism is yet to be clearly established.

(±)15-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. The biological activity of (±)15-HETE is similar to that of its constituent enantiomers (Item Nos. 34720 and 34710).

The diol resulting from the sEH opening of (±)11(12)-EET; contracts artery rings with approximately 70% of the magnitude of (±)11(12)-EET.

An aspirin-triggered lipoxin that inhibits LTB4-induced chemotaxis, adherence, and transmigration of the neutrophils with twice the potency of LXA4 demonstrating activity in the nM range.

Key urinary metabolite of PGD2; represents approximately 1% and 4% of the infused radiolabeled dose in monkeys and humans, respectively.

(±)12-HpETE is one of the six monohydroperoxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid (Item No. 90010) and consists of an equal mixture of the R and S isomers. Reduction of the hydroperoxide yields the more stable hydroxyl fatty acid (±)12-HETE (Item…

A proposed anti-inflammatory EPA metabolite that has been shown to promote inflammatory resolution in numerous disease models, including experimental colitis, asthma, atherosclerosis, type 2 diabetes, and HSV-1-induced stromal keratitis.

A 13R,14S-dihydroxy DHA formed by recombinant human macrophage 12-LO and sEH co-incubated with DHA; reduces neutrophil infiltration in a mouse model of peritonitis and enhances human macrophage phagocytosis of zymosan A.

A DHA epoxygenase metabolite detected in rat brain and spinal cord, as well as human serum, that acts as a substrate for sEH (Km = 5.1 µM); demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models and potently inhibits angiogenesis and tumor growth in in vitro assays.

Less potent than AEA (Item No. 90050) at the CB1 receptor (Ki = 600 versus 90 nM); inhibits FAAH.

An epoxygenase pathway product produced from EPA by CYP450 both in vitro and in vivo; its effects of remain to be determined.

A potential metabolite of PGD2, presumably produced from the known metabolite 13,14-dihydro-15-keto PGD2.

A DHA-derived product first identified in mouse inflammatory exudates; reduces neutrophil infiltration in vivo in both mouse peritonitis and dermal inflammation; enhances macrophage phagocytosis and efferocytosis.

An internal standard for the quantification of (±)14(15)-DiHET by GC- or LC-MS.

A minor CYP450 metabolite of arachidonic acid that stimulates vasodilation of rabbit kidney.

5(S)-HETrE is produced by the action of 5-LO when mead acid is the substrate. There are no literature reports of the biological activity or further metabolic fate of 5(S)-HETrE.

A potential cytochrome P450 metabolite of N-arachidonoyl taurine that may activate TRPV1 and TRPV4.

(±)9-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. The individual R and S isomers of racemic HETEs have been separated and identified using chiral phase HPLC. The racemic HETEs have been quantified as an index of lipid…

A positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes; inhibits PMV migration stimulated by LTB4 at a concentration of 10-7 M and inhibits LTB4-induced adhesion of PMNs with an IC₅₀ value of ~3 x 10-10 M.

(±)11-HDHA is an autoxidation product of DHA in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. DHA is metabolized to 11(S)-HDHA by human platelets and canine retina. In addition to 11(S)-HDHA, 14(S)-HDHA is also produced by platelets.…

(±)14(15)-EET-d11 contains 11 deuterium atoms at the 16, 16', 17, 17', 18, 18' ,19, 19' ,20, 20, and 20 positions. It is intended for use as an internal standard for the quantification of (±)14(15)-EET (Item No. 50651) by GC- or LC-MS.

15(R)-HEDE is isolated by the chromatographic resolution of (±)15-HEDE. There are no reports of biological activity associated with 15(R)-HEDE in the literature.

One of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid.

A 5-series LO derived from EPA; contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4, yet does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4.

(±)12-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. The biological activity of (±)12-HETE is similar to that of its constituent enantiomers (Item Nos. 34560 and 34570). It aggregates neutrophils with an EC₅₀…

A DHA epoxygenase metabolite found in rat brain and spinal cord that acts as a preferred substrate for sEH (Km = 3.2 µM); demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models and potently inhibits angiogenesis and tumor growth in in vitro assays.

(±)8-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid.